ActiGraph, the global leader in wearable technology for clinical research and drug development, has rebranded to Ametris to reflect its expanded data and technology platform, marking a new chapter in data-driven drug development and digital evidence generation. The new Ametris brand (pronounced Uh-ME-tris) reinforces the company’s vision of clinical trial modernization driven by more precise, continuous, and meaningful digital data. 

Recognized worldwide as a pioneer in actigraphy, ActiGraph has set the standard for real-world, continuous monitoring across academic and pharmaceutical studies since 2004. In the two decades since, the company has evolved from a wearable device manufacturer supporting academic and public health research into a global digital health solutions provider offering an integrated, end-to-end clinical trials platform spanning not only device-based data collection, but also AI-powered analytics, regulatory science, and operational support. Now as Ametris, the company will continue to pioneer cutting-edge digital health solutions that deliver validated insights to help researchers run smarter trials and make stronger decisions.  Much like imaging technology revolutionized the way we visualize the human body and disease, Ametris aims to redefine how we measure and understand health in motion.

The Ametris rebrand follows ActiGraph’s January 2025 acquisition of the Biofourmis Connect digital trial platform, including the AI-powered Biovitals Analytics Engine and RhythmAnalytics software as a medical device (SAMD) products, which significantly bolstered the company’s technology and scientific product portfolio. Now with the integrated Connect platform, Ametris provides a unified clinical trial software and data collection ecosystem, supporting proprietary ActiGraph wearable devices alongside a suite of validated third-party sensors and devices, including ECG patch, digital spirometer, and blood pressure cuff. Pharmaceutical sponsors can now rely on Ametris’ single scalable platform and deep scientific and operational expertise for the collection of a wide variety of digital endpoint and biomarker data across their clinical development programs. 

“This rebrand is a meaningful milestone for us, not just as a company, but as a team deeply committed to improving how clinical research is done," said Jeremy Wyatt, Chief Executive Officer of Ametris. "What began over 20 years ago as a focused effort to deliver high-quality wearable data has evolved into a broader mission to help our partners generate robust evidence, navigate regulatory complexity, and bring new therapies to patients faster. Our new identity embodies a commitment to scientific rigor, operational excellence, and our mission to transform the way clinical research is conducted.”

Although the company name has changed, the approach remains the same. Clients and partners can still expect a high bar of technical excellence for all Ametris products and solutions, and for the experienced team to deliver industry-leading scientific, operational, and regulatory expertise across every phase of every study. 

As Ametris, the company’s line of proprietary wearable devices, including the ActiGraph LEAP, CentrePoint Insight Watch, and wGT3X, as well as the ActiLife desktop software, will maintain the ActiGraph brand, ensuring continuity across scientific literature and regulatory documentation. 

Learn more at https://ametris.com/